Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 02 2019
Historique:
received: 16 10 2018
accepted: 11 01 2019
entrez: 27 2 2019
pubmed: 26 2 2019
medline: 15 9 2020
Statut: epublish

Résumé

Influenza A(H3N2) viruses evade human immunity primarily by acquiring antigenic changes in the haemagglutinin (HA). HA receptor-binding features of contemporary A(H3N2) viruses hinder traditional antigenic characterization using haemagglutination inhibition and promote selection of HA mutants. Thus, alternative approaches are needed to reliably assess antigenic relatedness between circulating viruses and vaccines. We developed a high content imaging-based neutralization test (HINT) to reduce antigenic mischaracterization resulting from virus adaptation to cell culture. Ferret reference antisera were raised using clinical specimens containing viruses representing recent vaccine strains. Analysis of viruses circulating during 2011-2018 showed that gain of an N158-linked glycosylation in HA was a molecular determinant of antigenic distancing between A/Hong Kong/4801/2014-like (clade 3C.2a) and A/Texas/50/2012-like viruses (clade 3C.1), while multiple evolutionary HA F193S substitution were linked to antigenic distancing from A/Switzerland/97152963/2013-like (clade 3C.3a) and further antigenic distancing from A/Texas/50/2012-like viruses. Additionally, a few viruses carrying HA T135K and/or I192T showed reduced neutralization by A/Hong Kong/4801/2014-like antiserum. Notably, this technique elucidated the antigenic characteristics of clinical specimens, enabling direct characterization of viruses produced in vivo, and eliminating in vitro culture, which rapidly alters the genotype/phenotype. HINT is a valuable new antigenic analysis tool for vaccine strain selection.

Identifiants

pubmed: 30804469
doi: 10.1038/s41598-019-39276-1
pii: 10.1038/s41598-019-39276-1
pmc: PMC6389938
doi:

Substances chimiques

Antibodies, Viral 0
Antigens, Viral 0
Hemagglutinin Glycoproteins, Influenza Virus 0
Immune Sera 0
Influenza Vaccines 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2676

Références

Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
J Virol. 2010 Jul;84(13):6769-81
pubmed: 20410266
Influenza Other Respir Viruses. 2012 Mar;6(2):142-52, e1-5
pubmed: 21819547
Mol Biol Evol. 2012 Aug;29(8):2063-71
pubmed: 22427709
Methods Mol Biol. 2012;865:115-25
pubmed: 22528156
Vaccine. 2012 Oct 5;30(45):6461-71
pubmed: 22917957
J Virol. 2013 Sep;87(17):9904-10
pubmed: 23824816
Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6
pubmed: 24080660
Mol Biol Evol. 2013 Dec;30(12):2725-9
pubmed: 24132122
Science. 2013 Nov 22;342(6161):976-9
pubmed: 24264991
Vaccine. 2014 Aug 20;32(37):4713-25
pubmed: 24582632
J Virol. 2014 Jun;88(12):7083-92
pubmed: 24719426
J Virol. 2014 Jul;88(13):7130-44
pubmed: 24719430
Hum Vaccin Immunother. 2015;11(6):1357-60
pubmed: 25844949
Wkly Epidemiol Rec. 2015 Jun 5;90(23):281-96
pubmed: 26050269
Influenza Other Respir Viruses. 2015 Nov;9(6):331-340
pubmed: 26073976
Cell Rep. 2015 Jul 7;12(1):1-6
pubmed: 26119736
Vaccine. 2015 Aug 26;33(36):4368-82
pubmed: 26148877
Wkly Epidemiol Rec. 2015 Oct 9;90(41):545-59
pubmed: 26454888
Sci Rep. 2015 Oct 16;5:15279
pubmed: 26472175
Influenza Other Respir Viruses. 2016 Mar;10(2):68-75
pubmed: 26589132
PLoS One. 2016 Mar 14;11(3):e0149916
pubmed: 26975056
J Infect Dis. 2016 Oct 1;214(7):1010-9
pubmed: 27190176
Nat Microbiol. 2016 May 23;1(6):16058
pubmed: 27572841
BMC Genomics. 2016 Sep 05;17:708
pubmed: 27595578
Virus Evol. 2016 Jul;2(2):null
pubmed: 27713835
J Clin Microbiol. 2016 Dec 28;55(1):145-154
pubmed: 27795346
Vaccine. 2017 Jan 3;35(1):46-52
pubmed: 27899226
Influenza Other Respir Viruses. 2017 May;11(3):263-274
pubmed: 28164446
PLoS Pathog. 2017 Mar 13;13(3):e1006271
pubmed: 28288189
Clin Infect Dis. 2017 Oct 30;65(10):1644-1651
pubmed: 29020179
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583
pubmed: 29109276
Wkly Epidemiol Rec. 2018 Mar 23;93(12):133-41
pubmed: 29569429
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):634-642
pubmed: 29879098

Auteurs

Patricia A Jorquera (PA)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.
CNI Advantage, LLC. 17 Executive Park Dr NE, Atlanta, GA, 30329, USA.

Vasiliy P Mishin (VP)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.

Anton Chesnokov (A)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.

Ha T Nguyen (HT)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.
Battelle Memorial Institute, 2987 Clairmont Rd, Suite 450, Atlanta, GA, 30329, USA.

Brian Mann (B)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.
Battelle Memorial Institute, 2987 Clairmont Rd, Suite 450, Atlanta, GA, 30329, USA.

Rebecca Garten (R)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.

John Barnes (J)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.

Erin Hodges (E)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.
CNI Advantage, LLC. 17 Executive Park Dr NE, Atlanta, GA, 30329, USA.

Juan De La Cruz (J)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.
Battelle Memorial Institute, 2987 Clairmont Rd, Suite 450, Atlanta, GA, 30329, USA.

Xiyan Xu (X)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.

Jackie Katz (J)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.

David E Wentworth (DE)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA.

Larisa V Gubareva (LV)

Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA, 30329, USA. lqg3@cdc.gov.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH